Lucida Medical gets CE Mark for AI software

By staff writers

June 2, 2021 -- U.K. startup Lucida Medical has received the CE Mark for its artificial intelligence (AI) software that detects prostate cancer.

Lucida's Prostate Intelligence (PI) application analyzes MRI scans to find cancer more accurately. Now that the software has received the CE Mark, it can be deployed within the U.K.'s National Health Service and European healthcare systems.

Lucida is a spin-out from Cambridge University that was founded by Dr. Evis Sala. The company received a round of investment funding in March from XTX Ventures and Prostate Cancer Research.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking